GO
Loading...

Bristol-Myers Squibb Co

More

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.

  • *Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.

  • Early movers: DRI, ORCL, BAC, TWTR, S, SHPG & more Friday, 20 Jun 2014 | 7:36 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.

  • NEW YORK, June 20- In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.

  • *Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.

  • Shire braces for takeover bids, hires Citi: Sources Monday, 16 Jun 2014 | 2:25 PM ET
    Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc.

    Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.

  • LONDON, June 16- London- listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the healthcare sector, sources familiar with the matter told Reuters.

  • Lightning Round: Bristol-Myers, Safeway & more Wednesday, 11 Jun 2014 | 6:50 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: Potash, GameStop & more Tuesday, 10 Jun 2014 | 6:48 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites

  • Investors eye Achillion for next big pharma deal Tuesday, 10 Jun 2014 | 2:20 PM ET
    Achillion web page

    Achillion's been a takeover target for years. But Merck's acquisition of Idenix may mean Achillion's time has come.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • June 10- Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, lifting a clinical hold that was imposed nearly a year ago.

  • Why Merck's Idenix deal is bad news for Gilead Monday, 9 Jun 2014 | 2:34 PM ET

    Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.

  • CHICAGO, June 3- AstraZeneca Plc, in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world's largest meeting of cancer doctors.

  • CHICAGO, June 3- AstraZeneca Plc, in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world's largest meeting of cancer doctors.

  • ZURICH, June 2- Roche is betting the same tools that made it the world's largest producer of cancer drugs will help it tackle the growing public health crisis of antibiotic resistance as regulators and politicians encourage fresh research.

  • Why these 3 biotech stocks are making big moves Monday, 2 Jun 2014 | 9:44 AM ET

    Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.

  • CHICAGO, June 1- U.S. researchers are finalizing plans to test two immunotherapy drugs made by Bristol-Myers Squibb Co on patients newly diagnosed with the most common form of deadly brain tumors in adults.

  • Immuno-what? How these cancer therapies work Thursday, 29 May 2014 | 12:27 PM ET

    A key theme at this year's ASCO meeting will be immunotherapies. How do these treatments work?